Global Non-alcoholic Steatohepatitis

Non-alcoholic Steatohepatitis Comprehensive Study by Type (Ocaliva, Elafibranor, Selonsertib, Cenicriviroc, Others), Application (Hypertension, Heart Disease, High Blood Lipid, Diabetes, Obesity), End Use Verticals (Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic Research Institutes) Players and Region - Global Market Outlook to 2030

Non-alcoholic Steatohepatitis Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Non-alcoholic steatohepatitis is a disease that develops in patients who are not alcoholics; it causes liver damage that is histologically indistinguishable from alcoholic hepatitis. Non-alcoholic steatohepatitis develops most often in patients with at least one of the following risk factors: obesity, and glucose intolerance, and dyslipidemia. Laboratory findings include elevations in aminotransferase levels. The biopsy is required to confirm the diagnosis. Treatment includes the elimination of causes and risk factors. Fat causes inflammation and damages cells in the liver and this has led to significant the growth of the non-alcoholic steatohepatitis market in the forecast period.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledAllergan PLC (Ireland), Galmed Pharmaceuticals (Israel), Intercept Pharmaceuticals Inc. (United States), Madrigal Pharmaceuticals (United States), Genfit SA (France), Novartis AG (Switzerland), Gilead Sciences Inc. (United States), Novo Nordisk A/S (Denmark), Merck & Co. (United States) and Viking Therapeutics (United States)


This growth is primarily driven by Increase in the Number of Expected Launch of Pipeline Drugs is a Significant factor in Stimulating Market Demand and The Rising Prevalence of NASH and Increasing Diabetic Population Globally.

Globally, a noticeable market trend is evident Increasing Prevalence of Obesity Coupled with Rising Adoption of the Sedentary Lifestyle Major Players, such as Allergan PLC (Ireland), Galmed Pharmaceuticals (Israel), Intercept Pharmaceuticals Inc. (United States), Madrigal Pharmaceuticals (United States), Genfit SA (France), Novartis AG (Switzerland), Gilead Sciences Inc. (United States), Novo Nordisk A/S (Denmark), Merck & Co. (United States) and Viking Therapeutics (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. The market for nonalcoholic steatohepatitis a severe form of nonalcoholic fatty liver disease offers substantial commercial opportunity for drug developers owing to the lack of approved agents and the disease’s large and growing prevalence.

Key Developments in the Market:
On 11 , April 2019 Gilead Sciences, Inc. has announced that new data from the company’s clinical research program in nonalcoholic steatohepatitis (NASH) being presented at The International Liver Congress™ 2019 in Vienna. This data support Gilead’s efforts to develop combination therapies to target different aspects of NASH.
In June 2022 – Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, today announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

Influencing Trend:
Increasing Prevalence of Obesity Coupled with Rising Adoption of the Sedentary Lifestyle

Market Growth Drivers:
Increase in the Number of Expected Launch of Pipeline Drugs is a Significant factor in Stimulating Market Demand and The Rising Prevalence of NASH and Increasing Diabetic Population Globally

Challenges:
High Treatment Cost

Restraints:
The Lethargic Drug Approval Process from the Regulatory Bodies

Opportunities:
Increasing Awareness about NAFLD/NASH is Creating Opportunity for Market

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Non-alcoholic Steatohepatitis Market
- Analysis about New Entrants in Non-alcoholic Steatohepatitis Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Non-alcoholic Steatohepatitis Study Sheds Light on
— The Non-alcoholic Steatohepatitis Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Non-alcoholic Steatohepatitis industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Non-alcoholic Steatohepatitis industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Ocaliva
  • Elafibranor
  • Selonsertib
  • Cenicriviroc
  • Others
By Application
  • Hypertension
  • Heart Disease
  • High Blood Lipid
  • Diabetes
  • Obesity
By End Use Verticals
  • Pharma & CRO Industry
  • Hospitals
  • Diagnostic Labs
  • Academic Research Institutes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Number of Expected Launch of Pipeline Drugs is a Significant factor in Stimulating Market Demand
      • 3.2.2. The Rising Prevalence of NASH and Increasing Diabetic Population Globally
    • 3.3. Market Challenges
      • 3.3.1. High Treatment Cost
    • 3.4. Market Trends
      • 3.4.1. Increasing Prevalence of Obesity Coupled with Rising Adoption of the Sedentary Lifestyle
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Non-alcoholic Steatohepatitis, by Type, Application, End Use Verticals and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Non-alcoholic Steatohepatitis (Value)
      • 5.2.1. Global Non-alcoholic Steatohepatitis by: Type (Value)
        • 5.2.1.1. Ocaliva
        • 5.2.1.2. Elafibranor
        • 5.2.1.3. Selonsertib
        • 5.2.1.4. Cenicriviroc
        • 5.2.1.5. Others
      • 5.2.2. Global Non-alcoholic Steatohepatitis by: Application (Value)
        • 5.2.2.1. Hypertension
        • 5.2.2.2. Heart Disease
        • 5.2.2.3. High Blood Lipid
        • 5.2.2.4. Diabetes
        • 5.2.2.5. Obesity
      • 5.2.3. Global Non-alcoholic Steatohepatitis by: End Use Verticals (Value)
        • 5.2.3.1. Pharma & CRO Industry
        • 5.2.3.2. Hospitals
        • 5.2.3.3. Diagnostic Labs
        • 5.2.3.4. Academic Research Institutes
      • 5.2.4. Global Non-alcoholic Steatohepatitis Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Non-alcoholic Steatohepatitis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan PLC (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Galmed Pharmaceuticals (Israel)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Intercept Pharmaceuticals Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Madrigal Pharmaceuticals (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Genfit SA (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Gilead Sciences Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novo Nordisk A/S (Denmark)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck & Co. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Viking Therapeutics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Non-alcoholic Steatohepatitis Sale, by Type, Application, End Use Verticals and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Non-alcoholic Steatohepatitis (Value)
      • 7.2.1. Global Non-alcoholic Steatohepatitis by: Type (Value)
        • 7.2.1.1. Ocaliva
        • 7.2.1.2. Elafibranor
        • 7.2.1.3. Selonsertib
        • 7.2.1.4. Cenicriviroc
        • 7.2.1.5. Others
      • 7.2.2. Global Non-alcoholic Steatohepatitis by: Application (Value)
        • 7.2.2.1. Hypertension
        • 7.2.2.2. Heart Disease
        • 7.2.2.3. High Blood Lipid
        • 7.2.2.4. Diabetes
        • 7.2.2.5. Obesity
      • 7.2.3. Global Non-alcoholic Steatohepatitis by: End Use Verticals (Value)
        • 7.2.3.1. Pharma & CRO Industry
        • 7.2.3.2. Hospitals
        • 7.2.3.3. Diagnostic Labs
        • 7.2.3.4. Academic Research Institutes
      • 7.2.4. Global Non-alcoholic Steatohepatitis Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Non-alcoholic Steatohepatitis: by Type(USD Million)
  • Table 2. Non-alcoholic Steatohepatitis Ocaliva , by Region USD Million (2018-2023)
  • Table 3. Non-alcoholic Steatohepatitis Elafibranor , by Region USD Million (2018-2023)
  • Table 4. Non-alcoholic Steatohepatitis Selonsertib , by Region USD Million (2018-2023)
  • Table 5. Non-alcoholic Steatohepatitis Cenicriviroc , by Region USD Million (2018-2023)
  • Table 6. Non-alcoholic Steatohepatitis Others , by Region USD Million (2018-2023)
  • Table 7. Non-alcoholic Steatohepatitis: by Application(USD Million)
  • Table 8. Non-alcoholic Steatohepatitis Hypertension , by Region USD Million (2018-2023)
  • Table 9. Non-alcoholic Steatohepatitis Heart Disease , by Region USD Million (2018-2023)
  • Table 10. Non-alcoholic Steatohepatitis High Blood Lipid , by Region USD Million (2018-2023)
  • Table 11. Non-alcoholic Steatohepatitis Diabetes , by Region USD Million (2018-2023)
  • Table 12. Non-alcoholic Steatohepatitis Obesity , by Region USD Million (2018-2023)
  • Table 13. Non-alcoholic Steatohepatitis: by End Use Verticals(USD Million)
  • Table 14. Non-alcoholic Steatohepatitis Pharma & CRO Industry , by Region USD Million (2018-2023)
  • Table 15. Non-alcoholic Steatohepatitis Hospitals , by Region USD Million (2018-2023)
  • Table 16. Non-alcoholic Steatohepatitis Diagnostic Labs , by Region USD Million (2018-2023)
  • Table 17. Non-alcoholic Steatohepatitis Academic Research Institutes , by Region USD Million (2018-2023)
  • Table 18. South America Non-alcoholic Steatohepatitis, by Country USD Million (2018-2023)
  • Table 19. South America Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 20. South America Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 21. South America Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 22. Brazil Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 23. Brazil Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 24. Brazil Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 25. Argentina Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 26. Argentina Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 27. Argentina Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 28. Rest of South America Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 29. Rest of South America Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 30. Rest of South America Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 31. Asia Pacific Non-alcoholic Steatohepatitis, by Country USD Million (2018-2023)
  • Table 32. Asia Pacific Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 33. Asia Pacific Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 34. Asia Pacific Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 35. China Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 36. China Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 37. China Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 38. Japan Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 39. Japan Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 40. Japan Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 41. India Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 42. India Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 43. India Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 44. South Korea Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 45. South Korea Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 46. South Korea Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 47. Taiwan Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 48. Taiwan Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 49. Taiwan Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 50. Australia Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 51. Australia Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 52. Australia Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 54. Rest of Asia-Pacific Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 55. Rest of Asia-Pacific Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 56. Europe Non-alcoholic Steatohepatitis, by Country USD Million (2018-2023)
  • Table 57. Europe Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 58. Europe Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 59. Europe Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 60. Germany Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 61. Germany Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 62. Germany Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 63. France Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 64. France Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 65. France Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 66. Italy Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 67. Italy Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 68. Italy Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 69. United Kingdom Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 70. United Kingdom Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 71. United Kingdom Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 72. Netherlands Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 73. Netherlands Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 74. Netherlands Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 75. Rest of Europe Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 76. Rest of Europe Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 77. Rest of Europe Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 78. MEA Non-alcoholic Steatohepatitis, by Country USD Million (2018-2023)
  • Table 79. MEA Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 80. MEA Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 81. MEA Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 82. Middle East Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 83. Middle East Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 84. Middle East Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 85. Africa Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 86. Africa Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 87. Africa Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 88. North America Non-alcoholic Steatohepatitis, by Country USD Million (2018-2023)
  • Table 89. North America Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 90. North America Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 91. North America Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 92. United States Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 93. United States Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 94. United States Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 95. Canada Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 96. Canada Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 97. Canada Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 98. Mexico Non-alcoholic Steatohepatitis, by Type USD Million (2018-2023)
  • Table 99. Mexico Non-alcoholic Steatohepatitis, by Application USD Million (2018-2023)
  • Table 100. Mexico Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2018-2023)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Non-alcoholic Steatohepatitis: by Type(USD Million)
  • Table 112. Non-alcoholic Steatohepatitis Ocaliva , by Region USD Million (2025-2030)
  • Table 113. Non-alcoholic Steatohepatitis Elafibranor , by Region USD Million (2025-2030)
  • Table 114. Non-alcoholic Steatohepatitis Selonsertib , by Region USD Million (2025-2030)
  • Table 115. Non-alcoholic Steatohepatitis Cenicriviroc , by Region USD Million (2025-2030)
  • Table 116. Non-alcoholic Steatohepatitis Others , by Region USD Million (2025-2030)
  • Table 117. Non-alcoholic Steatohepatitis: by Application(USD Million)
  • Table 118. Non-alcoholic Steatohepatitis Hypertension , by Region USD Million (2025-2030)
  • Table 119. Non-alcoholic Steatohepatitis Heart Disease , by Region USD Million (2025-2030)
  • Table 120. Non-alcoholic Steatohepatitis High Blood Lipid , by Region USD Million (2025-2030)
  • Table 121. Non-alcoholic Steatohepatitis Diabetes , by Region USD Million (2025-2030)
  • Table 122. Non-alcoholic Steatohepatitis Obesity , by Region USD Million (2025-2030)
  • Table 123. Non-alcoholic Steatohepatitis: by End Use Verticals(USD Million)
  • Table 124. Non-alcoholic Steatohepatitis Pharma & CRO Industry , by Region USD Million (2025-2030)
  • Table 125. Non-alcoholic Steatohepatitis Hospitals , by Region USD Million (2025-2030)
  • Table 126. Non-alcoholic Steatohepatitis Diagnostic Labs , by Region USD Million (2025-2030)
  • Table 127. Non-alcoholic Steatohepatitis Academic Research Institutes , by Region USD Million (2025-2030)
  • Table 128. South America Non-alcoholic Steatohepatitis, by Country USD Million (2025-2030)
  • Table 129. South America Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 130. South America Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 131. South America Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 132. Brazil Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 133. Brazil Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 134. Brazil Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 135. Argentina Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 136. Argentina Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 137. Argentina Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 138. Rest of South America Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 139. Rest of South America Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 140. Rest of South America Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 141. Asia Pacific Non-alcoholic Steatohepatitis, by Country USD Million (2025-2030)
  • Table 142. Asia Pacific Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 143. Asia Pacific Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 144. Asia Pacific Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 145. China Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 146. China Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 147. China Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 148. Japan Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 149. Japan Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 150. Japan Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 151. India Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 152. India Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 153. India Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 154. South Korea Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 155. South Korea Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 156. South Korea Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 157. Taiwan Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 158. Taiwan Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 159. Taiwan Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 160. Australia Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 161. Australia Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 162. Australia Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 163. Rest of Asia-Pacific Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 164. Rest of Asia-Pacific Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 165. Rest of Asia-Pacific Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 166. Europe Non-alcoholic Steatohepatitis, by Country USD Million (2025-2030)
  • Table 167. Europe Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 168. Europe Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 169. Europe Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 170. Germany Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 171. Germany Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 172. Germany Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 173. France Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 174. France Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 175. France Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 176. Italy Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 177. Italy Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 178. Italy Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 179. United Kingdom Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 180. United Kingdom Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 181. United Kingdom Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 182. Netherlands Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 183. Netherlands Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 184. Netherlands Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 185. Rest of Europe Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 186. Rest of Europe Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 187. Rest of Europe Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 188. MEA Non-alcoholic Steatohepatitis, by Country USD Million (2025-2030)
  • Table 189. MEA Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 190. MEA Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 191. MEA Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 192. Middle East Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 193. Middle East Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 194. Middle East Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 195. Africa Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 196. Africa Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 197. Africa Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 198. North America Non-alcoholic Steatohepatitis, by Country USD Million (2025-2030)
  • Table 199. North America Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 200. North America Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 201. North America Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 202. United States Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 203. United States Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 204. United States Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 205. Canada Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 206. Canada Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 207. Canada Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 208. Mexico Non-alcoholic Steatohepatitis, by Type USD Million (2025-2030)
  • Table 209. Mexico Non-alcoholic Steatohepatitis, by Application USD Million (2025-2030)
  • Table 210. Mexico Non-alcoholic Steatohepatitis, by End Use Verticals USD Million (2025-2030)
  • Table 211. Research Programs/Design for This Report
  • Table 212. Key Data Information from Secondary Sources
  • Table 213. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Non-alcoholic Steatohepatitis: by Type USD Million (2018-2023)
  • Figure 5. Global Non-alcoholic Steatohepatitis: by Application USD Million (2018-2023)
  • Figure 6. Global Non-alcoholic Steatohepatitis: by End Use Verticals USD Million (2018-2023)
  • Figure 7. South America Non-alcoholic Steatohepatitis Share (%), by Country
  • Figure 8. Asia Pacific Non-alcoholic Steatohepatitis Share (%), by Country
  • Figure 9. Europe Non-alcoholic Steatohepatitis Share (%), by Country
  • Figure 10. MEA Non-alcoholic Steatohepatitis Share (%), by Country
  • Figure 11. North America Non-alcoholic Steatohepatitis Share (%), by Country
  • Figure 12. Global Non-alcoholic Steatohepatitis share by Players 2023 (%)
  • Figure 13. Global Non-alcoholic Steatohepatitis share by Players (Top 3) 2023(%)
  • Figure 14. Global Non-alcoholic Steatohepatitis share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Allergan PLC (Ireland) Revenue, Net Income and Gross profit
  • Figure 17. Allergan PLC (Ireland) Revenue: by Geography 2023
  • Figure 18. Galmed Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 19. Galmed Pharmaceuticals (Israel) Revenue: by Geography 2023
  • Figure 20. Intercept Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Intercept Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 22. Madrigal Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 23. Madrigal Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 24. Genfit SA (France) Revenue, Net Income and Gross profit
  • Figure 25. Genfit SA (France) Revenue: by Geography 2023
  • Figure 26. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 28. Gilead Sciences Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Gilead Sciences Inc. (United States) Revenue: by Geography 2023
  • Figure 30. Novo Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 31. Novo Nordisk A/S (Denmark) Revenue: by Geography 2023
  • Figure 32. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Merck & Co. (United States) Revenue: by Geography 2023
  • Figure 34. Viking Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 35. Viking Therapeutics (United States) Revenue: by Geography 2023
  • Figure 36. Global Non-alcoholic Steatohepatitis: by Type USD Million (2025-2030)
  • Figure 37. Global Non-alcoholic Steatohepatitis: by Application USD Million (2025-2030)
  • Figure 38. Global Non-alcoholic Steatohepatitis: by End Use Verticals USD Million (2025-2030)
  • Figure 39. South America Non-alcoholic Steatohepatitis Share (%), by Country
  • Figure 40. Asia Pacific Non-alcoholic Steatohepatitis Share (%), by Country
  • Figure 41. Europe Non-alcoholic Steatohepatitis Share (%), by Country
  • Figure 42. MEA Non-alcoholic Steatohepatitis Share (%), by Country
  • Figure 43. North America Non-alcoholic Steatohepatitis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Allergan PLC (Ireland)
  • Galmed Pharmaceuticals (Israel)
  • Intercept Pharmaceuticals Inc. (United States)
  • Madrigal Pharmaceuticals (United States)
  • Genfit SA (France)
  • Novartis AG (Switzerland)
  • Gilead Sciences Inc. (United States)
  • Novo Nordisk A/S (Denmark)
  • Merck & Co. (United States)
  • Viking Therapeutics (United States)
Additional players considered in the study are as follows:
Bristol-Myers Squibb (United States) , Zydus Cadila (India)
Select User Access Type

Key Highlights of Report


Jan 2024 239 Pages 66 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Non-alcoholic Steatohepatitis Quantitative research analysis
Global Non-alcoholic Steatohepatitis Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Non-alcoholic Steatohepatitis market are Allergan PLC (Ireland), Galmed Pharmaceuticals (Israel), Intercept Pharmaceuticals Inc. (United States), Madrigal Pharmaceuticals (United States), Genfit SA (France), Novartis AG (Switzerland), Gilead Sciences Inc. (United States), Novo Nordisk A/S (Denmark), Merck & Co. (United States) and Viking Therapeutics (United States), to name a few.
is dominating the Non-alcoholic Steatohepatitis Market.
"High Treatment Cost" is seen as one of the major challenges by many Industry Players of Non-alcoholic Steatohepatitis Market
The Non-alcoholic Steatohepatitis market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Non-alcoholic Steatohepatitis market is expected to see a steady growth rate during projected year 2023 to 2030.

Know More About Global Non-alcoholic Steatohepatitis Report?

Have a Query? Click Here

Other Related Reports

Ophthalmology Drugs Comprehensive Study by Type (Lucentis (Ranibizumab), Eylea (Aflibercept), Avastin (Bevacizumab), Restasis (Cyclosporine), Alphagan (Brimonidine Tartrate), Lumigan (Bimatoprost), X...
$ 3750
Hodgkin Lymphoma Treatment Comprehensive Study by Type (Alocrest, ANK Program, Azacitidine, BMS-986016, BPX-501, Others), Application (Hospital, Clinic, Research Center), Treatment (Immunotherapy, Ra...
$ 3650
Cervical Cancer Diagnostic Tests Comprehensive Study by Type (Pap Test, HPV Typing Test, Colposcopy, Biopsy, Bimanual Pelvic Examination), Application (Hospitals, Specialty Clinics, Cancer and Radiat...
$ 3450
Overactive Bladder Treatment Comprehensive Study by Type (Self-Care (Absorbent Pads, Scheduled Toileting, Double Voiding, Bladder Training), Therapies (Biofeedback, Kegel Exercise), Medications (Blad...
$ 3750
Ankylosing Spondylitis Comprehensive Study by Application (Hospitals, Clinics, Ambulatory Surgical Centers), Route of Administration (Oral, Parenteral), Treatment Type (Nonsteroidal Anti-Inflammatory...
$ 3750
Infantile Spasms Therapeutics Comprehensive Study by Type (Monotherapy, Combination Therapy), Drug Form (Solid, Liquid), End Users (Infants, Children < 2 Years), Route of Administration (Oral, Parent...
$ 3500